- Gilead Sciences
This is our global website, intended for visitors seeking information on Gilead’s worldwide business Some content on this site is not intended for people outside the United States
- Careers at Gilead Sciences
Gilead, a global biopharma co pursuing innovation in virology, oncology and inflammation, offers a variety of career opportunities in an inclusive workplace where all can make an impact
- Gilead Sciences: Company
Learn about the biopharmaceutical company Gilead Sciences, including mission, vision, values, history, impact, leadership, therapeutic areas and other information
- Gilead Sciences Medicines
Access the list of approved Gilead therapies across virology including HIV, liver disease including hepatitis and primary biliary cholangitis, oncology inflammation
- Virology, Inflammation, Oncology Pipeline | Gilead
Through science and innovative partnerships, Gilead expands research and development programs in virology, oncology, inflammation Learn about our pipeline
- Gilead Sciences: Career Opportunities
Explore career opportunities and jobs at Gilead Sciences, a biopharma company with an inclusive culture where all employees can help build a healthier world
- Newsroom | Gilead
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial November 7, 2025
- Gilead Sciences, Inc. - Gilead Sciences Announces Fourth Quarter and . . .
“Gilead delivered another exceptionally strong full year and fourth quarter, with growth in our base business product sales of 8% for 2024 and 13% year-over-year for the fourth quarter,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer
|